Recombinant human serum albumin - Mitsubishi Tanabe Pharma

Drug Profile

Recombinant human serum albumin - Mitsubishi Tanabe Pharma

Alternative Names: Albrec; GB-1057; Medway; RU-10; RU-101

Latest Information Update: 21 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Mallinckrodt plc; Mitsubishi Tanabe Pharma Corporation
  • Class Acute-phase proteins; Albumins; Plasma expanders; Recombinant proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypoalbuminaemia
  • Phase II Dry eyes
  • Phase I Haematological disorders

Most Recent Events

  • 13 Feb 2018 Sucampo Pharmaceuticals has been acquired and merged into Mallinckrodt plc
  • 18 Feb 2016 Phase-I clinical trials in Haematological disorders in USA (unspecified route)
  • 10 Feb 2016 R-Tech Ueno terminates phase I trial in Dry eyes in Japan (UMIN000019291)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top